berbamine has been researched along with imatinib mesylate in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (66.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dong, Q; Gan, X; Lu, Q; Wu, D; Xu, R; Xu, X; Yu, XF; Yu, Y; Zhao, X | 1 |
Liang, Y; Wei, YL; Xu, L; Xu, XH; Zhao, XY | 1 |
Gu, Y; Ma, T; Qiu, X; Xie, J; Xu, R; Yu, Y; Zhang, L; Zhang, X | 1 |
Liang, Y; Wei, YL; Xu, L; Zhao, XY | 1 |
Huang, H; Liu, L; Luo, Y; Shi, J; Tan, Y; Wang, Y; Wu, G; Zhao, Y | 1 |
Chen, T; Fang, Y; Gan, X; Gan, Y; Gu, Y; Huang, L; Huang, W; Li, H; Lou, G; Meng, Z; Tang, J; Wang, K; Xu, G; Xu, R; Xu, X; Zhang, X; Zheng, S; Zhou, H | 1 |
1 trial(s) available for berbamine and imatinib mesylate
Article | Year |
---|---|
Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Benzamides; Benzylisoquinolines; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2011 |
5 other study(ies) available for berbamine and imatinib mesylate
Article | Year |
---|---|
Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity.
Topics: Alkaloids; Apoptosis; Benzamides; Benzylisoquinolines; Bone Marrow Cells; Caspase 3; Caspases; Dose-Response Relationship, Drug; Down-Regulation; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |
Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-X Protein; Benzamides; Benzylisoquinolines; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines | 2009 |
Berbamine derivatives: a novel class of compounds for anti-leukemia activity.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzylisoquinolines; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia; Piperazines; Pyrimidines | 2009 |
The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzylisoquinolines; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; G1 Phase; Genes, abl; Humans; I-kappa B Proteins; Imatinib Mesylate; Indicators and Reagents; Inhibitor of Apoptosis Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubule-Associated Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Piperazines; Pyrimidines; RNA, Messenger; Signal Transduction; Survivin; Tetrazolium Salts | 2009 |
CaMKII γ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Benzamides; Benzylisoquinolines; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinase Type 1; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; HEK293 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, SCID; Models, Molecular; Mutation; Neoplastic Stem Cells; Piperazines; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |